Items tagged with Advocacy

Stop TB Partnership and experts sound the alarm on urgent investments needed for new TB vaccines (post with simple image)

Progress in COVID-19 vaccine development shows the value of investing in vaccines, yet TB vaccine research received only 20% of needed funding in 2019.

CAB compensation survey (post with simple image)

Take a quick Community Advisory Board (CAB) compensation survey and help define how to best support CAB members!

Community-led action activating a human rights-based TB response: Launch of a policy brief in 5 languages (post with simple image)

'Activating a human rights-based TB response – a technical brief for policymakers and program implementers' is now available online in 5 languages - Bahasa, Hindi, Marathi, French and Spanish. It can also be accessed in English.

TB CAB evaluation survey (post with simple image)

Take a short survey and help evaluate the first 10 years of the Global TB CAB!

Substantial public investments in GeneXpert underscore need for affordable pricing (post with simple image)

PLOS ONE publishes TAG’s comprehensive analysis of public investments in the development of rapid technology for diagnosing infectious diseases.

(post with simple image)

Advocates ring the alarm on TB medicines and diagnostics stock outs across India (post with simple image)

Civil society networks in India call for the Ministry of Health and Family Welfare and the National TB Elimination Program to take urgent action.

International support for compulsory license to address access barriers to life-saving TB medicines (post with simple image)

Advocates urge the Indian government to issue compulsory licenses for patents on bedaquiline and delamanid to make the drugs more affordable and accessible.

New data shows COVID-19 combined with funding shortfalls are devastating efforts to end TB by 2030 (post with simple image)

Less than half of required funding has been provided globally with dramatic consequences as hundreds of thousands more die from TB.

Advocates urge Cepheid to reinstate plans to commercialize GeneXpert Omni (post with simple image)

Advocates call out Cepheid for canceling commercialization of the portable point-of-care GeneXpert Omni testing instrument and urge the company to reinstate plans to launch Omni, reiterating demands for Cepheid to reduce the price of GeneXpert tests to $5, inclusive of service and maintenance, across diseases.

Page 98 of 98 · Total posts: 0

←First 97 98